Skip to main content

Table 1 (abstract P70). Treatment-emergent adverse events reported by 1.5% or more patients in any galcanezumab dose-group.

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  

Galcanezumab

Event

Placebo

N=1451

n (%)

120-mg

N=705

n (%)

240-mg

N=730

n (%)

Combined N=1435

n (%)

Injection site pain

138 (9.5)

71 (10.1)

85 (11.6)

156 (10.9)

Nasopharyngitis

94 (6.5)

52 (7.4)

31 (4.3)†

83 (5.8)

Upper respiratory tract infection

60 (4.1)

31 (4.4)

36 (4.9)

67 (4.7)

Injection site reaction

14 (1.0)

22 (3.1)‡

45 (6.2)‡

67 (4.7)‡

Dizziness

41 (2.8)

20 (2.8)

20 (2.7)

40 (2.8)

Injection site erythema

20 (1.4)

20 (2.8)†

29 (4.0)‡

49 (3.4)‡

Sinusitis

31 (2.1)

20 (2.8)

19 (2.6)

39 (2.7)

Urinary tract infection

33 (2.3)

19 (2.7)

18 (2.5)

37 (2.6)

Fatigue

34 (2.4)

17 (2.4)

16 (2.2)

33 (2.3)

Injection site pruritus

2 (0.1)

15 (2.1)‡

24 (3.3)‡

39 (2.7)‡

Neck pain

21 (1.5)

15 (2.1)

6 (0.8)

21 (1.5)

Abdominal pain

24 (1.7)

13 (1.8)

6 (0.8)

19 (1.3)

Cough

19 (1.3)

12 (1.7)

13 (1.8)

25 (1.7)

Oropharyngeal pain

13 (0.9)

10 (1.4)

12 (1.6)

22 (1.5)

Bronchitis

17 (1.2)

9 (1.3)

11 (1.5)

20 (1.4)

Influenza

34 (2.3)

8 (1.1)

20 (2.7)

28 (2.0)

Constipation

8 (0.6)

7 (1.0)

11 (1.5)†

18 (1.3)†

Migraine

14 (1.0)

7 (1.0)

12 (1.6)

19 (1.3)

  1. †Indicates P < .05 compared with placebo
  2. ‡Indicates P < .001 compared with placebo